210 related articles for article (PubMed ID: 34824159)
1. Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1.
Darwich A; Silvestri A; Benmebarek MR; Mouriès J; Cadilha B; Melacarne A; Morelli L; Supino D; Taleb A; Obeck H; Sustmann C; Losurdo A; Masci G; Curigliano G; Kobold S; Penna G; Rescigno M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824159
[TBL] [Abstract][Full Text] [Related]
2. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
5. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
6. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
7. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
9. RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis.
Ma B; Herzog EL; Moore M; Lee CM; Na SH; Lee CG; Elias JA
Sci Rep; 2016 May; 6():26299. PubMed ID: 27198666
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
11. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
12. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.
Yang PS; Yu MH; Hou YC; Chang CP; Lin SC; Kuo IY; Su PC; Cheng HC; Su WC; Shan YS; Wang YC
Theranostics; 2022; 12(1):340-361. PubMed ID: 34987649
[No Abstract] [Full Text] [Related]
13. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
[TBL] [Abstract][Full Text] [Related]
14. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
[TBL] [Abstract][Full Text] [Related]
15. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
Li F; Liu S
Front Immunol; 2022; 13():1083462. PubMed ID: 36601109
[TBL] [Abstract][Full Text] [Related]
16. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
[TBL] [Abstract][Full Text] [Related]
17. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Miura D; Yoneyama K; Furuhata Y; Shimizu K
J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
Katz JD; Mitsuyasu R; Gottlieb MS; Lebow LT; Bonavida B
J Immunol; 1987 Jul; 139(1):55-60. PubMed ID: 3584988
[TBL] [Abstract][Full Text] [Related]
20. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]